Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-312 in Patients With Synucleinopathies
NCT05634876Phase 1Completed
- Sponsor
- NYU Langone Health
- Start
- May 2023
- Primary completion
- Feb 2025
- Modality
- Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ub-312 in multiple system atrophy (MSA) and Parkinson's disease (PD) (4 arms), sponsored by NYU Langone Health. Primary endpoints: Change in Serum Levels of anti-aSyn Antibodies from First Injection at Week 133 and Change in CSF Levels of anti-aSyn Antibodies from First Injection at Week 133. Started May 2023; status: completed.
02
Drugs
ub-312
03
Conditions
multiple system atrophy (MSA)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05634876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634876.